These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23861694)

  • 1. Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries.
    Paes B; Mitchell I; Li A; Harimoto T; Lanctôt KL
    Clin Dev Immunol; 2013; 2013():917068. PubMed ID: 23861694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS).
    Paes B; Mitchell I; Li A; Lanctôt KL;
    Eur J Clin Microbiol Infect Dis; 2012 Oct; 31(10):2703-11. PubMed ID: 22546928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
    Paes B; Mitchell I; Li A; Lanctôt KL
    Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
    Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
    Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palivizumab for the prevention of respiratory syncytial virus infection.
    Rogovik AL; Carleton B; Solimano A; Goldman RD
    Can Fam Physician; 2010 Aug; 56(8):769-72. PubMed ID: 20705882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D; Saleem M; Paes B; Mitchell I; Lanctôt KL
    Clin Infect Dis; 2019 Aug; 69(6):980-986. PubMed ID: 30517603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
    Banerji A; Panzov V; Young M; Lee BE; Mamdani M; Giles BL; Dennis M; Morel J; Bisson D; Paes BA; Hui C; Mahony J
    Can Respir J; 2014; 21(3):185-9. PubMed ID: 24367792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry.
    Cohen SA; Zanni R; Cohen A; Harrington M; VanVeldhuisen P; Boron ML;
    Pediatr Cardiol; 2008 Mar; 29(2):382-7. PubMed ID: 17926087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
    Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.
    DeVincenzo JP; Ambrose CS; Makari D; Weiner LB
    Hum Vaccin Immunother; 2016 Apr; 12(4):971-5. PubMed ID: 26889568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection.
    Lanari M; Vandini S; Arcuri S; Galletti S; Faldella G
    Clin Dev Immunol; 2013; 2013():359683. PubMed ID: 23840240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.